sitagliptin + metformin hydrochloride apc 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu
apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg
sitagliptin + metformin hydrochloride apc 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg
rosuvastatin + acetylsalicylic acid adamed 5 mg + 100 mg kapsułki twarde
adamed pharma s.a. - rosuvastatinum calicum + acidum acetylsalicylicum - kapsułki twarde - 5 mg + 100 mg
rosuvastatin + acetylsalicylic acid adamed 10 mg + 100 mg kapsułki twarde
adamed pharma s.a. - rosuvastatinum calicum + acidum acetylsalicylicum - kapsułki twarde - 10 mg + 100 mg
rosuvastatin + acetylsalicylic acid adamed 20 mg + 100 mg kapsułki twarde
adamed pharma s.a. - rosuvastatinum calicum + acidum acetylsalicylicum - kapsułki twarde - 20 mg + 100 mg
rosuvastatin medical valley 5 mg tabletki powlekane
medical valley invest ab - rosuvastatin calcium - tabletki powlekane - 5 mg
tadalafil mensil 10 mg tabletki powlekane
przedsiębiorstwo produkcji farmaceutycznej hasco-lek s.a. - tadalafilum - tabletki powlekane - 10 mg
doxycycline genoptim 100 mg kapsułki twarde
synoptis pharma sp. z o.o. - doxycyclini hyclas - kapsułki twarde - 100 mg
competact
cheplapharm arzneimittel gmbh - pioglitazone, metformina chlorowodorek - diabetes mellitus, type 2 - leki stosowane w cukrzycy - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
eucreas
novartis europharm limited - вилдаглиптин, metformina chlorowodorek - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.